Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170017 | 0.95 | HRH3 (0.56) | HRH3HRH4ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL4175928 | 0.83 | SMN1; SMN2 (0.49) | HRH3ALDH1A1KDM4ECYP2D6CYP2C19 | |
| SCHEMBL4167165 | 0.78 | SMN1; SMN2 (0.50) | HRH3ALDH1A1KDM4ECYP2D6CYP2C19 | |
| SCHEMBL7319627 | 0.77 | HRH3 (0.67) | HRH3HRH4ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL3440556 | 0.77 | HRH3 (0.67) | HRH3HRH4ALDH1A1KDM4ECYP2D6 | |
| Hydrochloric Acid SCHEMBL7329891 | 0.76 | HRH3 (0.64) | HRH3HRH4ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL4179842 | 0.76 | CYP19A1 (0.39) | — | |
| SCHEMBL13577677 | 0.75 | HRH3 (0.69) | HRH3HRH4ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL4277270 | 0.74 | HRH3 (1.00) | HRH3HRH4ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL30596544 | 0.74 | HRH3 (0.67) | HRH3HRH4ALDH1A1KDM4ECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | AMGEN INC. (US) | 2009-09-10 | — | — | US | claimed |
| EP-1963285-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | Amgen Inc. (US) | 2008-09-03 | — | — | EP | claimed |
| WO-2007067629-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2007-06-14 | — | — | WO | claimed |
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | AMGEN INC. (US) | 2009-09-10 | — | — | US | disclosed |
| EP-1963285-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | Amgen Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067629-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | BDKRB1, BDKRB2, VIPR1 | HRH3 14/4885HRH4 9/4885ALDH1A1 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.